ARMP Armata Pharmaceuticals, Inc.

AMEX
$4.56

Armata Pharmaceuticals, Inc. (ARMP) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.6% since its last earnings release on August 12, 2026.

Armata Pharmaceuticals Beat Consensus Estimates
Wednesday, August 12, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:30 PM ET
Earnings Whisper
-
vs ($0.57)
Rev est $900K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.72

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.

Sector

Healthcare

Industry

Biotechnology